DURHAM, NC, United States

Biomarck Pharmaceuticals, Ltd

www.biomarck.com
DURHAM, NC, United States

Time filter

Source Type

Patent
Biomarck Pharmaceuticals, Ltd and North Carolina State University | Date: 2016-07-06

The present invention relates to methods and compounds for treating or preventing cancer. Methods and compositions provided include including inhibiting or suppressing the development, maintenance, and proliferation of cancers, including blocking or inhibiting cancer cell metastasis.


Grant
Agency: Department of Health and Human Services | Branch: | Program: STTR | Phase: Phase I | Award Amount: 201.50K | Year: 2014

DESCRIPTION (provided by applicant): The objective of the proposed project is to advance the development of novel peptides targeting MARCKS (Myristoylated Alanine-Rich C Kinase Substrate) protein as platform drug molecules for the treatment of Acute Lung Injury (ALI) and its more severe form, Acute Respiratory Distress Syndrome (ARDS), thereby providing the first pharmacologic therapeutic for this condition. ALI/ARDS is a major cause of respiratory failure; worldwide, over 1 million cases occur annually, with ~ 200,000 adult and 15,000 pediatric cases per year in the U.S. This disorder is characterized by a large influx of neutrophils to the lung as part of an acute inflammatory response, injury to epithelial and endothelial cell barriers, and pulmonary edema, all of which lead to respiratory failure. Treatment options are presently limited to mechanical ventilation, a supportive therapy which still results in an in-hospital mortality rate of ~40% in the U.S., with few survivors discharged to home due t


Patent
North Carolina State University and Biomarck Pharmaceuticals, Ltd | Date: 2014-04-07

The present invention relates to methods and compounds for treating or preventing cancer. Methods and compositions provided include including inhibiting or suppressing the development, maintenance, and proliferation of cancers, including blocking or inhibiting cancer cell metastasis.


Patent
Biomarck Pharmaceuticals, Ltd | Date: 2011-12-28

Peptides are provided that comprise less than 24 amino acids. The peptides have an amino acid sequence selected from the group consisting of: (a) an amino acid sequence having from 4 to 23 contiguous amino acids of a reference sequence PEPTIDE 1; (b) an amino acid sequence substantially identical to the sequence defined in (a); and (c) a variant of the amino acid sequence defined in (a). Also provided is a non-myristoylated MANS peptide. Various methods of using the peptides are also provided.


Grant
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: SBIR | Phase: Phase II | Award Amount: 3.00M | Year: 2013

DESCRIPTION provided by applicant Hypersecretion of mucus into the respiratory airways is a major contributing factor in several lung diseases including chronic pulmonary disease COPD asthma cystic fibrosis allergic rhinitis and bronchiectasis Despite the obvious medical importance there presently are no effective therapies to control excess mucus secretion in these diseases and very few potential therapeutic targets We discovered that a specific protein called MARCKS is a key molecule in the mucus secretary pathway Based on this finding BioMarck developed a novel peptide BIO which inhibited mucus hypersecretion as well as release of inflammatory mediators in human airway epithelial cells in culture and in various rodent models BIO being a dual function inhibitor mucus secretion and inflammation is an ideal drug to potentially treat various lung diseases including COPD With funding from SBIR grants BioMarck continued work on this project and has recently successfully completed under an active IND a day proof of concept Phase A clinical study in COPD patients suffering from chronic bronchitis with its lead compound BIO This SBIR Phase II Bridge grant application will allow BioMarck to undertake a day Phase B multi center double blind dose selection clinical study with BIO with COPD patients suffering from chronic bronchitis A successful completion of the proposed project will allow BioMarck to select a dose level for the final Phase clinical study Worldwide the social and economic burden of COPD is enormous COPD being the th leading cause of death accounts for over million deaths worldwide Although there are more than different drugs currently available in the market the patients and the care providers are desperate for effective drugs for the treatment of COPD BIO by reducing both excess mucus and airway inflammation has the potential to be a first in class drug to effectively treat this patien population PUBLIC HEALTH RELEVANCE More than million individuals worldwide suffer from COPD As many as million people were diagnosed with COPD and an equal number of undiagnosed in the U S during NIH Morbidity and Mortality Chart Book COPD is known to have caused deaths in the U S during the same year and is now the rd leading cause of death The incidence of COPD around the world is rapidly increasing and is largely driven by an increase in the number of smokers and increasing air pollution The World Health Organization estimates that million people died of COPD worldwide in COPD is characterized by progressive destructive changes of airway and lung architecture that leads to limitations in airflow These physiological changes lead to poorly reversible airway obstruction and impairment of gas exchange in the lungs The most common clinical expression of COPD is a combination of chronic bronchitis and emphysema Chronic cough frequent clearing of the throat wheezing and shortness of breath after mild exertion are common symptoms COPD is a slowly progressive mostly irreversible disease characterized by a gradual loss of lung function Hypersecretion of mucus into the lungs is a major contributing factor in several lung diseases including COPD asthma and cystic fibrosis Despite the obvious medical importance there presently are no effective therapies to control excess mucus secretion in these diseases We discovered that a specific protein called MARCKS is a key molecule in the mucus secretion Based on this finding BioMarck is developing a novel compound BIO as a potential new treatment for patients with COPD With funding from SBIR BioMarck has recently completed a proof of concept early clinical study of short duration in a small number of COPD patients BioMarck intends to continue working on this project and to develop this potential drug to help needy COPD patients


Patent
Biomarck Pharmaceuticals, Ltd | Date: 2015-03-04

The present invention includes methods of inhibiting or suppressing cellular secretory processes. More specifically the present invention relates to inhibiting or reducing the release of inflammatory mediators from inflammatory cells by inhibiting the mechanism associated with the release of inflammatory mediators from granules in inflammatory cells. In this regard, the present invention discloses an intracellular signaling mechanism that illustrates several novel intracellular targets for pharmacological intervention in disorders involving secretion of inflammatory mediators from vesicles in inflammatory cells. Peptide fragments and variants thereof of MANS peptide as disclosed in the present invention are useful in such methods.


Patent
Biomarck Pharmaceuticals, Ltd | Date: 2014-11-10

Peptides are provided that comprise less than 24 amino acids. The peptides have an amino acid sequence selected from the group consisting of: (a) an amino acid sequence having from 4 to 6 contiguous amino acids of a reference sequence PEPTIDE 1; (b) an amino acid sequence substantially identical to the sequence defined in (a); and (c) a variant of the amino acid sequence defined in (a). Also provided is a non-myristoylated MANS peptide. Various methods of using the peptides are also provided.


Patent
Biomarck Pharmaceuticals, Ltd | Date: 2014-04-23

The present invention includes methods of inhibiting or suppressing cellular secretory processes. More specifically the present invention relates to inhibiting or reducing the release of inflammatory mediators from inflammatory cells by inhibiting the mechanism associated with the release of inflammatory mediators from granules in inflammatory cells. In this regard, the present invention discloses an intracellular signaling mechanism that illustrates several novel intracellular targets for pharmacological intervention in disorders involving secretion of inflammatory mediators from vesicles in inflammatory cells. Peptide fragments and variants thereof of MANS peptide as disclosed in the present invention are useful in such methods.


Patent
Biomarck Pharmaceuticals, Ltd | Date: 2013-06-28

Peptides are provided that comprise less than 24 amino acids. The peptides have an amino acid sequence selected from the group consisting of: (a) an amino acid sequence having from 4 to 6 contiguous amino acids of a reference sequence PEPTIDE 1; (b) an amino acid sequence substantially identical to the sequence defined in (a); and (c) a variant of the amino acid sequence defined in (a). Also provided is a non-myristoylated MANS peptide. Various methods of using the peptides are also provided.


DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/kdxrbb/acute_lung_injury) has announced the addition of the "Acute Lung Injury - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Lung Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Lung Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Loading Biomarck Pharmaceuticals, Ltd collaborators
Loading Biomarck Pharmaceuticals, Ltd collaborators